Compare Stocks: STOK, RYTM, MIRM, and LNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LNTH Lantheus	$101.00 +1.0%	$104.06	$47.25 ▼ $111.86	$6.51B	-0.06	827,461 shs	1.48 million shs
MIRM Mirum Pharmaceuticals	$112.59 +4.7%	$109.92	$50.25 ▼ $130.00	$6.56B	0.48	583,863 shs	575,866 shs
RYTM Rhythm Pharmaceuticals	$105.74 -0.7%	$100.34	$74.50 ▼ $122.20	$7.30B	1.88	608,484 shs	534,585 shs
STOK Stoke Therapeutics	$30.04 +1.9%	$30.39	$12.40 ▼ $40.22	$1.84B	1.17	600,430 shs	689,483 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LNTH Lantheus	-2.57%	-4.41%	-8.74%	+18.18%	+38.50%
MIRM Mirum Pharmaceuticals	-4.39%	-6.27%	-12.76%	+10.27%	+109.69%
RYTM Rhythm Pharmaceuticals	-1.40%	+2.46%	-3.19%	+30.94%	+24.41%
STOK Stoke Therapeutics	+0.31%	+1.80%	-8.98%	-9.90%	+135.84%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LNTH Lantheus	$101.00 +1.0%	$104.06	$47.25 ▼ $111.86	$6.51B	-0.06	827,461 shs	1.48 million shs
MIRM Mirum Pharmaceuticals	$112.59 +4.7%	$109.92	$50.25 ▼ $130.00	$6.56B	0.48	583,863 shs	575,866 shs
RYTM Rhythm Pharmaceuticals	$105.74 -0.7%	$100.34	$74.50 ▼ $122.20	$7.30B	1.88	608,484 shs	534,585 shs
STOK Stoke Therapeutics	$30.04 +1.9%	$30.39	$12.40 ▼ $40.22	$1.84B	1.17	600,430 shs	689,483 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LNTH Lantheus	-2.57%	-4.41%	-8.74%	+18.18%	+38.50%
MIRM Mirum Pharmaceuticals	-4.39%	-6.27%	-12.76%	+10.27%	+109.69%
RYTM Rhythm Pharmaceuticals	-1.40%	+2.46%	-3.19%	+30.94%	+24.41%
STOK Stoke Therapeutics	+0.31%	+1.80%	-8.98%	-9.90%	+135.84%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LNTH Lantheus	2.67	Moderate Buy	$109.71	8.63% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$143.40	27.34% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$138.73	31.20% Upside
STOK Stoke Therapeutics	2.73	Moderate Buy	$43.00	43.14% Upside

Current Analyst Ratings Breakdown

Latest STOK, RYTM, MIRM, and LNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$120.00 ➝ $115.00
7/28/2026	LNTH Lantheus	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/27/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$145.00
7/17/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$115.00 ➝ $125.00
7/15/2026	LNTH Lantheus	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform ➝ Market Outperform	$115.00 ➝ $120.00
7/13/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
7/13/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$44.00
7/9/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$97.00 ➝ $129.00
7/7/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$137.00 ➝ $141.00

(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LNTH Lantheus	$1.55B	4.25	$6.29 per share	16.07	$16.43 per share	6.15
MIRM Mirum Pharmaceuticals	$521.31M	13.17	$0.05 per share	2,201.49	$6.12 per share	18.40
RYTM Rhythm Pharmaceuticals	$189.76M	38.19	N/A	N/A	$2.08 per share	50.84
STOK Stoke Therapeutics	$184.42M	10.14	N/A	N/A	$6.17 per share	4.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LNTH Lantheus	$233.56M	$4.15	24.34	18.77	N/A	18.05%	29.32%	15.00%	8/5/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$13.61	N/A	866.23	N/A	-140.24%	-11.28%	-3.84%	8/5/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.13	N/A	N/A	N/A	-93.33%	-203.25%	-44.99%	8/4/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$2.81	N/A	N/A	N/A	-529.20%	-48.84%	-42.27%	8/3/2026 (Estimated)

Latest STOK, RYTM, MIRM, and LNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LNTH Lantheus	$1.33	N/A	N/A	N/A	$362.45 million	N/A
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7279	N/A	N/A	N/A	$166.03 million	N/A
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.82	N/A	N/A	N/A	$67.66 million	N/A
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.82	N/A	N/A	N/A	$4.89 million	N/A
5/7/2026	Q1 2026	LNTH Lantheus	$1.25	$1.46	+$0.21	$1.80	$354.48 million	$377.33 million
5/7/2026	Q1 2026	STOK Stoke Therapeutics	-$0.80	-$0.79	+$0.01	-$0.79	$6.48 million	$6.23 million
5/6/2026	Q1 2026	MIRM Mirum Pharmaceuticals	-$0.75	-$13.43	-$12.68	-$13.43	$148.21 million	$159.88 million
5/5/2026	Q1 2026	RYTM Rhythm Pharmaceuticals	-$0.86	-$0.83	+$0.03	-$0.83	$55.78 million	$60.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LNTH Lantheus	0.47	2.83	2.64
MIRM Mirum Pharmaceuticals	1.28	2.09	1.99
RYTM Rhythm Pharmaceuticals	N/A	4.17	3.89
STOK Stoke Therapeutics	N/A	8.99	8.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LNTH Lantheus	99.06%
MIRM Mirum Pharmaceuticals	N/A
RYTM Rhythm Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
LNTH Lantheus	1.70%
MIRM Mirum Pharmaceuticals	8.32%
RYTM Rhythm Pharmaceuticals	5.90%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LNTH Lantheus	1,193	65.11 million	64.00 million	Optionable
MIRM Mirum Pharmaceuticals	140	60.98 million	55.91 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
STOK Stoke Therapeutics	100	62.28 million	56.30 million	Optionable

STOK, RYTM, MIRM, and LNTH Headlines

Recent News About These Companies

OMERS ADMINISTRATION Corp Invests $1.35 Million in Stoke Therapeutics, Inc. $STOK

July 30 at 5:12 AM | marketbeat.com

Stoke Therapeutics (STOK) Expected to Release Earnings on Monday

July 29 at 11:10 AM | marketbeat.com

Stoke Therapeutics, Inc. $STOK Position Increased by Redmile Group LLC

July 29 at 5:52 AM | marketbeat.com

EcoR1 Capital LLC Takes Position in Stoke Therapeutics, Inc. $STOK

July 28 at 4:01 AM | marketbeat.com

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates

July 27 at 7:43 PM | finance.yahoo.com

Troluce Capital Advisors LLC Buys Shares of 652,800 Stoke Therapeutics, Inc. $STOK

July 27 at 6:23 AM | marketbeat.com

Granahan Investment Management LLC Has $10.93 Million Stock Holdings in Stoke Therapeutics, Inc. $STOK

July 25, 2026 | marketbeat.com

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

July 24, 2026 | theglobeandmail.com

Siren L.L.C. Sells 252,000 Shares of Stoke Therapeutics, Inc. $STOK

July 24, 2026 | marketbeat.com

Stoke Therapeutics Inc.

July 21, 2026 | barrons.com

Stoke Therapeutics: Its Dravet Syndrome Lead Asset Enters The Last Stretch

July 19, 2026 | seekingalpha.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

July 16, 2026 | businesswire.com

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group

July 14, 2026 | marketbeat.com

Stoke Tx appoints Thomas McCauley as CSO

July 13, 2026 | thepharmaletter.comT

Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer

July 13, 2026 | finance.yahoo.com

Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK

July 12, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts

July 10, 2026 | marketbeat.com

Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK

July 7, 2026 | marketbeat.com

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...

June 30, 2026 | finance.yahoo.com

Jonathan Allan Sells 1,457 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

June 19, 2026 | insidertrades.com

Stoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, RYTM, MIRM, and LNTH Company Descriptions

Lantheus NASDAQ:LNTH

$101.00 +1.00 (+1.00%)

Closing price 04:00 PM Eastern

Extended Trading

$100.50 -0.50 (-0.50%)

As of 07:34 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Mirum Pharmaceuticals NASDAQ:MIRM

$112.59 +5.02 (+4.67%)

Closing price 04:00 PM Eastern

Extended Trading

$112.89 +0.30 (+0.27%)

As of 07:34 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$105.74 -0.79 (-0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$105.76 +0.03 (+0.02%)

As of 07:34 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$30.04 +0.56 (+1.90%)

Closing price 04:00 PM Eastern

Extended Trading

$30.03 -0.01 (-0.03%)

As of 07:34 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, RYTM, MIRM, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, RYTM, MIRM, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, RYTM, MIRM, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, RYTM, MIRM, and LNTH Company Descriptions

Lantheus NASDAQ:LNTH

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, RYTM, MIRM, and LNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, RYTM, MIRM, and LNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, RYTM, MIRM, and LNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, RYTM, MIRM, and LNTH Company Descriptions

Lantheus NASDAQ:LNTH

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools